37 studies found for:    " April 15, 2009":" May 15, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" April 15, 2009":" May 15, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Atazanavir (ATV) 300 mg;   Drug: Atazanavir (ATV) 400 mg;   Drug: Ritonavir (rtv) 100 mg;   Drug: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs);   Drug: Etravirine (ETR) 200 mg;   Drug: Tenofovir disoproxil fumarate (TDF) 300 mg
2 Completed
Has Results
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
Conditions: HIV Infection;   HIV;   Acquired Immunodeficiency Syndrome
Interventions: Drug: etravirine (ETR, TMC125);   Drug: efavirenz (EFV)
3 Completed Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid
Conditions: Human Immunodeficiency Virus Infections;   HIV Infections
Interventions: Biological: tgAAC09;   Other: Formulation buffer
4 Completed Empowerment Intervention for Young Women - Phase I
Conditions: HIV;   Empowerment;   HIV Infections
Intervention: Behavioral: Prevention Empowerment Intervention for Young Women
5 Completed HIV- Risk Reduction Behavioral Intervention for Commercial Sex Workers in Yerevan Armenia
Conditions: HIV Prevention;   HIV Infections
Intervention: Behavioral: HIV risk reduction intervention
6 Completed Linkage to Care - Part II
Conditions: HIV;   Care-seeking;   HIV Infections
Interventions: Other: Case Management;   Other: Snowball sampling;   Other: Referral Lists
7 Completed Efficacy and Safety of Single Versus Double Ritonavir-Boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: ritonavir-boosted PI-based second line treatments;   Drug: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
8 Completed Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Langerhans Cell Histiocytosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aggressive NK-cell Leukemia;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Malignancies;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Clear Cell Renal Cell Carcinoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV Infection;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Mast Cell Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid/NK-cell Acute Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Osteolytic Lesions of Multiple Myeloma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Renal Cell Cancer;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Stage IV Renal Cell Cancer;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: sunitinib malate;   Other: pharmacological study;   Other: laboratory biomarker analysis
9 Completed Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment
Conditions: Human Immunodeficiency Virus;   Chronic Hepatitis C
Interventions: Drug: pegylated interferon-alpha (Pegasys);   Drug: ribavirin (COPEGUS)
10 Completed Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects
Condition: HIV Infections
Intervention: Drug: Maraviroc
11 Completed Dose Reduction of Lopinavir in Children
Condition: HIV Infections
Interventions: Drug: Lopinavir/ritonavir standard dose According to WHO simplified dosing table;   Drug: Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)
12 Completed Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: ADVAX;   Biological: TBC-M4;   Other: Placebo
13 Unknown  Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
Condition: HIV Infections
Interventions: Drug: darunavir, ritonavir, rosuvastatin;   Drug: rosuvastatin, darunavir, ritonavir
14 Completed
Has Results
Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut
Condition: HIV Infections
Interventions: Drug: raltegravir;   Drug: Study NNRTI;   Drug: Study PI
15 Unknown  Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection
Condition: HIV Infections
Interventions: Drug: Truvada (tenofovir/emitricitabine);   Drug: Kaletra (lopinavir/ritonavir)
16 Recruiting High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Conditions: Cryptococcal Meningitis;   HIV Infections
Interventions: Drug: Fluconazole;   Drug: Amphotericin B
17 Active, not recruiting Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Conditions: HIV Infections;   Memory
Intervention:
18 Completed TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
Condition: HIV Infections
Intervention: Drug: TMC207; nevirapine
19 Completed Prevalence and Determinants of Chronic Obstructive Pulmonary Disease (COPD) in HIV+ Patients
Conditions: HIV Infections;   COPD
Intervention:
20 Unknown  Atazanavir and Lamivudine for Treatment Simplification
Condition: HIV Infections
Interventions: Drug: Lamiduvine (Epivir);   Drug: Atazanavir (Reyataz);   Drug: Ritonavir (Norvir)

Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results
Indicates status has not been verified in more than two years